Introduction
thrombotic/thromboembolic, polycythemia
ESSENTIAL THROMBOCYTHEMIA, POLYCYTHEMIA VERA, MYELOPROLIFERATIVE NEOPLASM, POLYCYTHEMIA, EVENTS
Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) that is caused by somatic gain-of-function mutations in the Treatment of PV is mainly directed at preventing thrombotic/thromboembolic events [Two randomized phase 3 trials [We report here the results from the futility analysis of the PV cohort treated within the phase 2b clinical trial entitled “Ruxolitinib versus best available therapy in patients with high-risk polycythemia Vera or high-risk essential thrombocythemia” (Ruxo-BEAT; NCT02577926) to assess the efficacy and tolerability of ruxolitinib in untreated PV pts.